Status:
COMPLETED
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
6+ years
Brief Summary
The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tr...
Eligibility Criteria
Inclusion
- Patients of either sex, including children over 6 years
- Chronic obstructive respiratory tract disease. Every doctor was asked to include in this study the first patients coming after each other, who were treated for the first time with Berodual® metered dose inhaler (MDI)
Exclusion
- Contraindications listed in the Instructions for Use/Summary of Product Characteristics of Berodual® metered-dose inhaler
Key Trial Info
Start Date :
January 1 1999
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
713 Patients enrolled
Trial Details
Trial ID
NCT02231424
Start Date
January 1 1999
Last Update
September 4 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.